Holen Sie sich die Stockscreener-App
18.02
7.84%
1.31
Handel nachbörslich:
17.95
-0.07
-0.39%
Schlusskurs vom Vortag:
$16.71
Offen:
$16.93
24-Stunden-Volumen:
707.78K
Relative Volume:
0.38
Marktkapitalisierung:
$1.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-230.32M
KGV:
-5.1108
EPS:
-3.5259
Netto-Cashflow:
$-196.04M
1W Leistung:
+11.03%
1M Leistung:
-1.10%
6M Leistung:
-68.04%
1J Leistung:
-54.58%
1-Tages-Spanne:
$16.88
$18.03
1-Wochen-Bereich:
$16.03
$18.03
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.02 | 1.20B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
Breakout Watch: What is the Moat Score of MoonLake Immunotherapeutics2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake surges 65% after InvestingPro Fair Value identifies opportunity By Investing.com - Investing.com Australia
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook By Investing.com - Investing.com India
MoonLake upgraded to Outperform from Underperform at Wolfe Research - TipRanks
HLXC,MLTX Volatility & Greeks - Finviz
MLTX Upgraded to 'Outperform' by Wolfe Research with Target Pric - GuruFocus
HLXC,MLTX Forecast, Target Price - Finviz
This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday - Benzinga
Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途牛牛
Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform" - MarketBeat
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook - Investing.com
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - AOL.com
MoonLake upgraded at Rothschild & Co Redburn citing potential FDA nod for lead drug - MSN
MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval - MSN
Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Maintains Target Price $6 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase - simplywall.st
Technical Reactions to MLTX Trends in Macro Strategies - Stock Traders Daily
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade - MarketBeat
Rothschild & Co Redburn Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Cuts Target Price to $40 - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Rothschild & Co Redburn to Buy Rating - MarketBeat
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn - TipRanks
Rothschild Redburn upgrades Moonlake stock on regulatory clarity - Investing.com
Rothschild & Co upgrades MoonLake Immunotherapeutics (MLTX) - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Earnings Beat: Will MoonLake Immunotherapeutics be affected by tariffs2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
RBC Capital Downgrades MoonLake Immunotherapeutics (MLTX) - MSN
This fund acquired $28 million worth of a struggling immunotherapy stock last quarter. What important information should long-term investors consider? - Bitget
Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MLTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $70 - 富途牛牛
Clear Street raises Moonlake stock price target on IL-17 data - Investing.com Nigeria
MoonLake price target raised to $70 from $45 at Clear Street - TipRanks
Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st
Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily
Rhenman & Partners Asset Management AB Buys 162,000 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):